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In this editorial for the first issue of Current Oncolo-
gy’s sixteenth year, I am pleased to begin with the im-
portant announcement that Dr. Martin Chasen has
graciously accepted the position of managing editor.
His assumption of this role will allow the journal to
process its substantially increased quantity of submis-
sions in a more timely manner. Everyone is working
hard to achieve a turnaround measurable in weeks
rather than in months. Welcome, Dr. Chasen!
The major thrust of Current Oncology continues to
be the field of education, and in this issue, readers will
find manuscripts from Dr. Nahum Sonenberg and col-
leagues discussing the feasibility of targeted therapy for
mTOR-dependent tumours with specific inhibitors (per-
haps timely, in view of our soon-to-be-published sup-
plement on developments surrounding the management
of renal cell cancer). In a  similar vein, Dr. Paul Williams
and colleagues  use the Updates and Developments in
Oncology section to discuss the concept of “genomacy,”
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the development and validation of potential genomic drug
response predictor models, made increasing complex
in the era of combination therapies.
Dr. Peter Ellis and colleagues report on their efforts
to develop consensus recommendations on the use of
epidermal growth factor receptor tyrosine kinase inhibi-
tors in non-small-cell lung cancer—a challenging task
given the sheer number of studies (often with confusing
messages) that have been published of late. The impor-
tance of this review is reflected in the effects of the
new global data on patient care and provincial budgets.
As we, the Editorial Board, reiterate our ongoing
thanks to contributors who write topical reviews by
request, we are also particularly encouraged by the
increasing visibility of the journal and the growth in its
perceived value as a venue for the publication of origi-
nal clinical research. To ensure that Current Oncology
continues to develop into a leading force in the cancer
field is our collective goal.